- Home
- CGBD vs KURA Comparison
CGBD vs KURA Comparison
Compare CGBD & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- KURA
- Stock Information
- Founded
- CGBD 2012
- KURA 2014
- Country
- CGBD United States
- KURA United States
- Employees
- CGBD N/A
- KURA N/A
- Industry
- CGBD Finance: Consumer Services
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGBD Finance
- KURA Health Care
- Exchange
- CGBD Nasdaq
- KURA Nasdaq
- Market Cap
- CGBD 1.0B
- KURA 561.9M
- IPO Year
- CGBD 2017
- KURA N/A
- Fundamental
- Price
- CGBD $14.24
- KURA $6.44
- Analyst Decision
- CGBD Hold
- KURA Strong Buy
- Analyst Count
- CGBD 3
- KURA 12
- Target Price
- CGBD $14.00
- KURA $24.50
- AVG Volume (30 Days)
- CGBD 429.7K
- KURA 1.4M
- Earning Date
- CGBD 08-04-2025
- KURA 08-07-2025
- Dividend Yield
- CGBD 12.97%
- KURA N/A
- EPS Growth
- CGBD N/A
- KURA N/A
- EPS
- CGBD 1.30
- KURA N/A
- Revenue
- CGBD $225,447,000.00
- KURA $67,991,000.00
- Revenue This Year
- CGBD $14.16
- KURA $125.04
- Revenue Next Year
- CGBD $5.83
- KURA $83.75
- P/E Ratio
- CGBD $10.91
- KURA N/A
- Revenue Growth
- CGBD N/A
- KURA N/A
- 52 Week Low
- CGBD $13.12
- KURA $5.41
- 52 Week High
- CGBD $18.74
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- CGBD 57.99
- KURA 59.02
- Support Level
- CGBD $13.76
- KURA $5.65
- Resistance Level
- CGBD $14.49
- KURA $6.46
- Average True Range (ATR)
- CGBD 0.24
- KURA 0.26
- MACD
- CGBD 0.05
- KURA 0.07
- Stochastic Oscillator
- CGBD 70.41
- KURA 97.73
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.